Basic Information
| LncRNA/CircRNA Name | RHPN1-AS1 |
| Synonyms | NA |
| Region | GRCh38_8:143366631-143368548 |
| Ensemble | ENSG00000254389 |
| Refseq | NR_026785 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Gefitinib | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | NSCLC tissues, cell lines (A549, H1975, H1299, HCC827, PC9 and 16HBE) |
| Expression Pattern | down-regulated |
| Function Description | In this study, RHPN1-AS1 was observed to be downregulated in gefitinib resistant patients and NSCLC cell lines. Besides, decreased expression of RHPN1-AS1 was found to be associated with poor prognosis of NSCLC patients. RHPN1-AS1 knockdown conferred gefitinib resistance to gefitinib sensitive NSCLC cells, whereas the overexpression of RHPN1-AS1 sensitized gefitinib resistant NSCLC cells to gefitinib treatment. In addition, RHPN1-AS1 overexpression promoted the gefitinib-induced cell apoptosis and cell mobility under gefitinib treatment. Mechanistically, RHPN1-AS1 was found to positively regulate the expression of TNFSF12 by directly interacting with miR-299-3p. Collectively, RHPN1-AS1 modulates gefitinib resistance through miR-299-3p/TNFSF12 pathway in NSCLC. |
| Pubmed ID | 30010468 |
| Year | 2018 |
| Title | The lncRNA RHPN1-AS1 Downregulation Promotes Gefitinib Resistance by Targeting miR-299-3p/TNFSF12 Pathway in NSCLC |
External Links
| Links for RHPN1-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |